Intravenous Immunoglobulin Therapy for Refractory Myositis.

• MORIGUCHI Masato

  The Institute of Rheumatology, Tokyo Women's Medical College

• SUZUKI Takahiro

  The Institute of Rheumatology, Tokyo Women's Medical College

• TATEISHI Mutsuto

  The Institute of Rheumatology, Tokyo Women's Medical College

• HARA Masako

  The Institute of Rheumatology, Tokyo Women's Medical College

• KASHIWAZAKI Sadao

  The Institute of Rheumatology, Tokyo Women's Medical College

抄録

The efficacy of polyvalent intravenous immunoglobulin therapy (IVIG) was evaluated in three patients with refractory myositis. Patients refractory to conventional therapy, such as corticosteroid administration, corticosteroid or cyclophosphamide pulse therapy [2 with dermatomyositis (DM), 1 with polymyositis (PM)] were treated with IVIG (0.4 g/kg daily) for 5 days. Clinical improvement was apparent within 1-2 months after IVIG and persisted for 19-23 months (DM patients) and 12 months (PM patient). No adverse effects were observed. Thus, IVIG may be considered an effective therapy for refractory myositis.<br>(Internal Medicine 35: 663-667, 1996)

収録刊行物

• Internal Medicine

  Internal Medicine 35 (8), 663-667, 1996

  一般社団法人 日本内科学会

キーワード

• polymyositis
• dermatomyositis
• interstitial pneumonia
• intravenous cyclophosphamide therapy

詳細情報

• CRID: 1390001204868590464
• NII論文ID: 10007004138
• NII書誌ID: AA10827774
• DOI: 10.2169/internalmedicine.35.663
• COI: 1:STN:280:ByiD2M%2FgtFM%3D
• ISSN: 13497235
• ISSN: 09182918
• PubMed: 8894745
• Web Site: http://www.jstage.jst.go.jp/article/internalmedicine1992/35/8/35_8_663/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/1997089128
• 本文言語コード: en
• データソース種別:
  • JaLC
  • Crossref
  • PubMed
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可